

Spain

Population 2015

46 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.26 (0.26–0.27)	0.57 (0.57–0.58)
Mortality (HIV+TB only)	0.054 (<0.01–0.27)	0.12 (0–0.58)
Incidence (includes HIV+TB)	5.5 (4.7–6.4)	12 (10–14)
Incidence (HIV+TB only)	0.4 (0.34–0.48)	0.87 (0.73–1)
Incidence (MDR/RR-TB)**	0.042 (0.016–0.069)	0.09 (0.03–0.15)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.18 (0.092–0.26)	2 (1.5–2.6)	2.2 (1.5–2.9)
Males	0.21 (0.14–0.28)	3.1 (2.4–3.8)	3.3 (2.6–4.1)
Total	0.39 (0.29–0.49)	5.1 (4.7–5.6)	5.5 (4.7–6.4)

TB case notifications, 2015	
Total cases notified	4 191
Total new and relapse	4 026
- % tested with rapid diagnostics at time of diagnosis	11%
- % with known HIV status	
- % pulmonary	74%
- % bacteriologically confirmed among pulmonary	82%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	73% (63–85)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.06 (0.03–0.09)

TB/HIV care in new and relapse TB patients, 2015		Number	(%)
Patients with known HIV-status who are HIV-positive			
- on antiretroviral therapy			

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			25 (10–40)
Estimated % of TB cases with MDR/RR-TB	0.44% (0.12–1.1)	7.1% (3.3–13)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: , XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	58%	4 689
Previously treated cases, excluding relapse, registered in 2014	52%	228
HIV-positive TB cases, all types, registered in 2014	39%	200
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB